InspireMD, Inc. (NYSE MKT: NSPR) seeks to utilize its proprietary MGuard™ with MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events, and the company intends to pursue applications of this MicroNet technology in coronary, carotid (CGuardTM), neurovascular, and peripheral artery procedures, according to the company’s website (see here: www.InspireMD.com). SNNLive spoke with Alan Milinazzo, President & CEO of InspireMD, Inc. at the Dawson James Small Cap Growth Conference 2015 in Jupiter, FL.
In this video interview, Mr. Milinazzo and our host discuss the following topics:
- Overview of InspireMD, Inc.
- How the company’s technology works
- How the technology affect patient care
- The approval process
- Where the science and technology comes from
- Comments on reimbursement
- Mr. Milinazzo’s background
Since speaking with Mr. Milinazzo, the company made the following announcements:
For more information about InspireMD, Inc., go to: www.InspireMD.com
© 2017 Stock News Now
Supported by Superior Web Solutions